WELIREG (belzutifan) + LENVIMA
Advanced Renal Cell Carcinoma
Phase 3Positive results, FDA review
Key Facts
About Eisai
Eisai is a Japanese pharmaceutical giant with a strong commitment to human health care (hhc), focusing on addressing unmet medical needs in neurology, oncology, and neglected tropical diseases. The company has achieved significant breakthroughs in Alzheimer's treatment with Lecanemab and maintains a robust oncology portfolio including multi-targeted kinase inhibitors. Eisai is also deeply committed to global health initiatives, providing treatments for neglected tropical diseases in developing countries while maintaining strong financial performance as a publicly traded company.
View full company profileOther Advanced Renal Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Cabozantinib | Exelixis | Phase 3 |